{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:31:21Z","timestamp":1786570281628,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019888","name":"University of Kentucky College of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20:GM130456"],"award-info":[{"award-number":["P20:GM130456"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dmd.2026.100340","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:23:33Z","timestamp":1780417413000},"page":"100340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduction of secondary 3-keto bile acids by aldo-keto reductase 1C1 and 1C4"],"prefix":"10.1016","volume":"54","author":[{"given":"Keith D.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham K.","family":"Thomason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9142-5706","authenticated-orcid":false,"given":"Lindsay C.","family":"Czuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.dmd.2026.100340_bib1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","article-title":"Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades","volume":"55","author":"Hofmann","year":"2014","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100340_bib2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","article-title":"Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression","volume":"125","author":"Claudel","year":"2003","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.dmd.2026.100340_bib3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100340_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100340_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20230934","article-title":"Bile salt signaling and bile salt-based therapies in cardiometabolic disease","volume":"138","author":"Groenen","year":"2024","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.dmd.2026.100340_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","article-title":"Review: microbial transformations of human bile acids","volume":"9","author":"Guzior","year":"2021","journal-title":"Microbiome"},{"issue":"3","key":"10.1016\/j.dmd.2026.100340_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI107233","article-title":"Triketocholanoic (dehydrocholic) acid. Hepatic metabolism and effect on bile flow and biliary lipid secretion in man","volume":"52","author":"Soloway","year":"1973","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.dmd.2026.100340_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1172\/JCI113143","article-title":"Cyclical oxidation-reduction of the C3 position on bile acids catalyzed by rat hepatic 3 alpha-hydroxysteroid dehydrogenase. I. Studies with the purified enzyme, isolated rat hepatocytes, and inhibition by indomethacin","volume":"80","author":"Takikawa","year":"1987","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.dmd.2026.100340_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI112829","article-title":"3 alpha-hydroxysteroid dehydrogenase activity of the Y' bile acid binders in rat liver cytosol. Identification, kinetics, and physiologic significance","volume":"79","author":"Stolz","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.dmd.2026.100340_bib10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.dmd.2026.100340_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.cbi.2014.12.004","article-title":"The rate-determining steps of aldo-keto reductases (AKRs), a study on human steroid 5beta-reductase (AKR1D1)","volume":"234","author":"Chen","year":"2015","journal-title":"Chem Biol Interact"},{"issue":"46","key":"10.1016\/j.dmd.2026.100340_bib12","doi-asserted-by":"crossref","first-page":"33484","DOI":"10.1074\/jbc.M703414200","article-title":"Elucidation of a complete kinetic mechanism for a mammalian hydroxysteroid dehydrogenase (HSD) and identification of all enzyme forms on the reaction coordinate: the example of rat liver 3alpha-HSD (AKR1C9)","volume":"282","author":"Cooper","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100340_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/er.2018-00089","article-title":"Structural and functional biology of aldo-keto reductase steroid-transforming enzymes","volume":"40","author":"Penning","year":"2019","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.dmd.2026.100340_bib14","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1124\/dmd.123.001358","article-title":"CYP2D6 activity is correlated with changes in plasma concentrations of taurocholic acid during pregnancy and postpartum in CYP2D6 extensive metabolizers","volume":"51","author":"Czuba","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100340_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/cts.12632","article-title":"Determinants of cytochrome P450 2D6 mRNA levels in healthy human liver tissue","volume":"12","author":"Ning","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.dmd.2026.100340_bib17","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.bmcl.2011.01.076","article-title":"Probing the inhibitor selectivity pocket of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis","volume":"21","author":"El-Kabbani","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.dmd.2026.100340_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jb\/mvx041","article-title":"Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily","volume":"162","author":"Hara","year":"2017","journal-title":"J Biochem"},{"key":"10.1016\/j.dmd.2026.100340_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12944-017-0551-1","article-title":"Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study","volume":"16","author":"Feng","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"7","key":"10.1016\/j.dmd.2026.100340_bib20","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-2275(20)38074-3","article-title":"Fasting levels of monoketonic bile acids in human peripheral and portal circulation","volume":"23","author":"Bjorkhem","year":"1982","journal-title":"J Lipid Res"},{"issue":"43","key":"10.1016\/j.dmd.2026.100340_bib21","doi-asserted-by":"crossref","first-page":"13054","DOI":"10.1021\/bi060591r","article-title":"Multiple steps determine the overall rate of the reduction of 5alpha-dihydrotestosterone catalyzed by human type 3 3alpha-hydroxysteroid dehydrogenase: implications for the elimination of androgens","volume":"45","author":"Jin","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.dmd.2026.100340_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.steroids.2013.10.012","article-title":"Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism","volume":"79","author":"Rizner","year":"2014","journal-title":"Steroids"},{"issue":"4","key":"10.1016\/j.dmd.2026.100340_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03602530802431439","article-title":"The aldo-keto reductase superfamily and its role in drug metabolism and detoxification","volume":"40","author":"Barski","year":"2008","journal-title":"Drug Metab Rev"},{"issue":"12","key":"10.1016\/j.dmd.2026.100340_bib24","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1211\/0022357045020","article-title":"Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol","volume":"56","author":"Breyer-Pfaff","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.dmd.2026.100340_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109746","article-title":"Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): functions, regulation, and structural insights of inhibitors","volume":"351","author":"Chu","year":"2022","journal-title":"Chem Biol Interact"},{"issue":"9","key":"10.1016\/j.dmd.2026.100340_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100142","article-title":"Metabolic activation of flunitrazepam via nitroreduction mediated by aldo-keto reductase 1C3","volume":"53","author":"Marques","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"Pt 2","key":"10.1016\/j.dmd.2026.100340_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/bj3130373","article-title":"Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells","volume":"313","author":"Hara","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.dmd.2026.100340_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2025.101481","article-title":"Human aldo-keto reductase (AKR) 1C1 and 1C2 act as coactivators of pregnane X receptor, a master regulator of drug-metabolizing and gluconeogenesis enzymes","volume":"62","author":"Mitamura","year":"2025","journal-title":"Drug Metab Pharmacokinet"},{"issue":"11","key":"10.1016\/j.dmd.2026.100340_bib29","doi-asserted-by":"crossref","first-page":"10784","DOI":"10.1074\/jbc.M313308200","article-title":"Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action","volume":"279","author":"Steckelbroeck","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100340_bib30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bcp.2007.09.008","volume":"75","author":"Byrns","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100340_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/BJ20101804","article-title":"Stereospecific reduction of 5beta-reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5beta-reductase pathway","volume":"437","author":"Jin","year":"2011","journal-title":"Biochem J"},{"issue":"38","key":"10.1016\/j.dmd.2026.100340_bib32","doi-asserted-by":"crossref","first-page":"12028","DOI":"10.1021\/bi0489762","article-title":"Dissection of the physiological interconversion of 5alpha-DHT and 3alpha-diol by rat 3alpha-HSD via transient kinetics shows that the chemical step is rate-determining: effect of mutating cofactor and substrate-binding pocket residues on catalysis","volume":"43","author":"Heredia","year":"2004","journal-title":"Biochemistry"},{"issue":"34","key":"10.1016\/j.dmd.2026.100340_bib33","doi-asserted-by":"crossref","first-page":"10161","DOI":"10.1021\/bi010919a","article-title":"Crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase\/bile acid binding protein complexed with NADP(+) and ursodeoxycholate","volume":"40","author":"Jin","year":"2001","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.dmd.2026.100340_bib34","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1124\/dmd.123.001402","article-title":"Quantitative analysis of mRNA and protein expression levels of aldo-keto reductase and short-chain dehydrogenase\/reductase isoforms in the human intestine","volume":"51","author":"Hirosawa","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100340_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117044","article-title":"Inter-individual variability, differential tissue abundance, and sub-cellular localization of human aldo-keto reductases (AKRs) and hydroxy-steroid dehydrogenases (HSDs)","volume":"239","author":"Bachhav","year":"2025","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100340_bib36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1113\/EP092001","article-title":"The ins and outs of liver fat metabolism: the effect of phenotype and diet on risk of intrahepatic triglyceride accumulation","volume":"110","author":"Smith","year":"2025","journal-title":"Exp Physiol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100340_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4093\/dmj.2020.0039","article-title":"Distinct dose-dependent association of free fatty acids with diabetes development in nonalcoholic fatty liver disease patients","volume":"45","author":"Li","year":"2021","journal-title":"Diabetes Metab J"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:07:22Z","timestamp":1786568842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0090955626006094"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100340","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of secondary 3-keto bile acids by aldo-keto reductase 1C1 and 1C4","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100340"}}